Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00085943 | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks | PHASE3 | COMPLETED | 866 | — | — | May 1, 2004 | - | May 16, 2011 | 119 | United States, Austria +12 |
| Name | Type | Description |
|---|---|---|
| LEXIVA (GW433908) | DRUG | - |
| Ritonavir | DRUG | - |
| KALETRA | DRUG | - |
| EPIVIR | DRUG | - |
| Ziagen | DRUG | - |
| Abacavir/Lamivudine | DRUG | - |
| Fosamprenavir | DRUG | - |
Inclusion Criteria: * HIV infected subjects that are naive to anti-HIV therapy. * History of a positive HIV test. * At least 1000 copies/mL of HIV in their blood as screening. Exclusion Criteria: * Active HIV-related diseases. * Taking other investigational drugs. * Pregnant or breastfeeding fema...